<DOC>
	<DOCNO>NCT02323139</DOCNO>
	<brief_summary>This study phase Ib add-on study combination LDE255 azacitidine patient without marrow response least 6 cycle azacitidine .</brief_summary>
	<brief_title>A Study LDE255 Combination With Azacitidine High Risk Myelodysplastic Syndrome Patients</brief_title>
	<detailed_description>Dose escalation LDE255 perform time use roll 6 design determine safety combination azacitidine . The start dose 400 mg. Azacitidine continue maximum tolerate dose ( MTD ) . Evaluation base cycle 1 toxicity profile . Once MTD determine , 20 additional patient treat recommended dose .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . High risk myelodysplastic syndrome ( MDS ) accord International Prognosis Scoring System ( IPSS ) acute myeloid leukemia ( AML ) low blast count ( Bone marrow blast count 20 30 % ) non proliferative chronic myelomonocytic leukemia ( CMML ) ( White blood cell ( WBC ) 13 G/L ) 2 . Age 18 year 3 . Performance Status 0 2 4 . Patient must recover toxicity prior treatment regimen ( common toxicity criterion adverse event ( CTCAE ) ) grade 1 nonhematological toxicity , return baseline hematological value ) 5 . Patient must treat azacitidine single agent least 6 cycle 6 . According International work group ( IWG ) 2006 criterion , patient may a/ stable disease , OR b/ disease progression limit patient loss hematological improvement without bone marrow progression . Patients bone marrow progression ( i.e . increase bone marrow blast count 50 % ) include . 7 . Bone marrow blast count 10 % 30 % 8 . Adequate liver renal function : Serum creatinine le 1.5 x institutional upper limit normal ( ULN ) Total bilirubin le 1.5 x ULN unless consider due Gilbert 's syndrome Alanine aminotransferase ( ALT , SGPT ) , aspartate aminotransferase ( AST , SGOT ) less 2.5 x ULN unless consider due organ leukemic involvement Creatine Kinase le 1.5 x ULN 9 . Able understand sign write informed consent 10 . Women childbearing potential must agree use effective contraception without interruption throughout study 3 month end treatment 11 . Men must agree conceive treatment use effective contraception treatment period ( include period dose reduction temporary suspension ) 3 month end treatment partner childbearing potential . 1 . Allogeneic stem cell transplantation ( SCT ) within last 4 month and/or active graft versus host disease ( GVHD ) , autologous SCT within last 4 week . Patient suitable allogeneic transplantation identify allogeneic donor ( Extension phase ) . 2 . Active central nervous system ( CNS ) leukemic involvement . 3 . Major surgery within 2 week initiation study medication . 4 . Concurrent uncontrolled medical condition may interfere potentially affect interpretation study . 5 . Unable take oral drug , lack physical integrity upper gastrointestinal tract , know malabsorption syndrome . 6 . Patients unresolved diarrhea &gt; CTCAE grade 2 . 7 . Patients previously treat systemic LDE225 Hh pathway inhibitor . 8 . Patients neuromuscular disorder ( i.e . inflammatory myopathy , muscular dystrophy , amyotrophic lateral sclerosis spinal muscular atrophy ) concomitant treatment drug recognize cause rhabdomyolysis , 3hydroxy3methylglutarylcoenzyme A ( HMG CoA ) inhibitor ( statin ) , clofibrate gemfibrozil . Pravastatin may use necessary , extra caution . 9 . Patients plan embark new physical activity , strenuous exercise , result significant increase plasma creatine kinase level study treatment . Strenuous muscular activity MUST avoid within 1 week blood test study . 10 . Patient history cardiac dysfunction include follow : Myocardial infarction document elevated cardiac enzyme persistent regional wall abnormality assessment life ventricular ejection fraction ( LVEF ) function within last six month . History document congestive heart failure ( New York Association functional classification IIIIV ) . Documented cardiomyopathy . Familial history long QT syndrome . 11 . Patient active cardiac disease include follow : Corrected QT ( QTc ) interval correct heart rate use Fridericia 's formula ( QTcF ) &gt; 450 msec male &gt; 470 msec female screen electrocardiogram ( ECG ) . Angina pectoris require use antianginal medication . Ventricular arrhythmia except benign premature ventricular contraction . Supraventricular nodal arrhythmia require pacemaker control medication . Conduction abnormality require pacemaker . Valvular disease document compromise cardiac function . Symptomatic pericarditis . 12 . Use investigational drug within 30 day 5 halflives initiation study medication , whichever longer . 13 . Patients receive treatment medication know moderate strong inhibitor inducer cytochrome P450 ( CYP ) isoenzyme 3A4/5 ( CYP3A4 ) drug metabolize CYP isoenzyme 2B6 ( CYP2B6 ) CYP isoenzyme 2C9 ( CYP2C9 ) narrow therapeutic index , discontinue start treatment LDE225 . Medications strong CYP3A4/5 inhibitor discontinue least 7 day strong CYP3A4/5 inducer least 2 week prior start treatment LDE225 . 14 . Patients exclude use warfarin ( substrate CYP2C9 ) necessary substitute since LDE225 competitive inhibitor CYP2C9 base vitro data . 15 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive human chorionic gonadotropin laboratory test ( &gt; 5 milliInternational Unit ( mIU ) /mL ) . 16 . Patients willing apply highly effective contraception study duration define final dose study treatment . Women childbearing potential , defined woman physiologically capable become pregnant , must use highly effective contraception study 6 month final dose study treatment . Highly effective contraception define either : Total abstinence : When line prefer usual lifestyle patient . Periodic abstinence ( i.e. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . Sterilization : Patient surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least six week take study treatment . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment . Male partner sterilization ( appropriate postvasectomy documentation absence sperm ejaculate ) . [ For female study patient , vasectomised male partner sole partner patient ] . Use combination follow ( a+b ) : Placement nonhormonal intrauterine device ( IUD ) nonhormonal intrauterine system ( IUS ) . Barrier method contraception : Condom Occlusive cap ( diaphragm cervical vault cap ) spermicidal foam/gel/film/cream/vaginal suppository . Note : Hormonal contraception method ( i.e . oral , injected , implant ) allow rule study drug decrease effectiveness hormonal contraception . Note : Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( i.e . age appropriate , history vasomotor symptom ) six month spontaneous amenorrhea serum follicle stimulate hormone ( FSH ) level &gt; 40 mIU/mL estradiol &lt; 20 pg/mL surgical bilateral oophorectomy ( without hysterectomy ) least six week ago . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential . Male patient must use highly effective ( double barrier ) method contraception ( i.e. , spermicidal gel plus condom ) entire duration study , continue use contraception refrain father child 6 month follow study drug . A condom require use also vasectomize men order prevent delivery study treatment via seminal fluid . 17 . Known human immunodeficiency virus ( HIV ) positivity . 18 . Patients unwilling unable comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>High risk MDS</keyword>
	<keyword>Azacitidine</keyword>
	<keyword>LDE255</keyword>
</DOC>